参考文献/References:
[1]石远凯,孙燕.临床肿瘤内科手册第6版[M].北京:人民卫生出版社,2014,690-696.
[2]罗健,孙燕,周生余.中国癌症患者化学生物治疗生活质量量表的编制[J].中华肿瘤杂志,1997(6):437-441.
[3]Magda Spella,Anastasios D,Georgios T.Switching off malignant pleural effusion formation-fantasy or future[J].Thorac Dis.2015,7(6):1009-1020.
[4]Jussuf T,Kaifi MD PhD,Toth J W,et al.Multidisciplinary management of malignant pleural effusion [J].Journal of Surgical Oncology,2012,105(7):731.
[5]Aelony Y.Best current therapy for patients with malignant pleural effusion[J].Respiration;international review of thoracic diseases,2013,85(1):13.
[6]Chen Y,Liang B,Zhao Y J,et al.Transcription expression and clinical significance of vascular endothelial growth factor mRNA and endostatin mRNA in pleural effusions of patients with lung cancer[J].Diagnostic Cytopathology,2012,40(4):287-291.
[7]Gomes F G,Nedel F,Alves A M,et al.Tumor angiogenesis and lymphangiogenesis:tumor endothelial crosstalk and cellular microenvironmental signaling mechanisms[J].Life Sciences,2013,92(2):101-107.
[8]Lin J,Yun D U,Tao L I,et al.Differential expression of vascular endothelial growth factor-A,-C and -D for the diagnosis and prognosis of cancer patients with malignant effusions[J].Oncology Letters,2015,10(2):667-674.
[9]Ma X,Yao Y,Yuan D,et al.Recombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice[J].Plos One,2012,7(12):e53449.
[10]李延文,李子明,陆舜.恩度胸腔灌注治疗恶性胸腔积液的作用研究[J].实用临床医药杂志,2011, 15(9):78-80.
[11]马恩奇,邹利乐,袁丹.恩度单用与恩度联合化疗治疗恶性胸腔积液的临床观察[J].中国医药科学,2012(15):52-53.
[12]Ma S,Chen F,Ye X,et al.Intravenous microemulsion of docetaxel containing an anti-tumor synergistic ingredient(Brucea javanica oil):formulation and pharmacokinetics[J].International Journal of Nanomedicine,2013,8(Issue 1):4045.
[13]Biaoxue R,Xiguang C,Hua L,et al.Thoracic perfusion of recombinant human endostatin(Endostar)combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions:a systematic evaluation and meta-analysis[J].Bmc Cancer,2016,16(1):888.